Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Dalpiciclib, Anastrozole, Pyrotinib, and Trastuzumab in ER+/HER2+ Breast Cancer
NCT04236310Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of dalpiciclib in Estrogen Receptor Positive Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer, sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
dalpiciclib
03
Conditions
Estrogen Receptor Positive Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Beyond the preview
Go deeper on NCT04236310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04236310.